See more : Boliden AB (publ) (BOLIF) Income Statement Analysis – Financial Results
Complete financial analysis of Zhejiang Cheng Yi Pharmaceutical Co., Ltd. (603811.SS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Zhejiang Cheng Yi Pharmaceutical Co., Ltd., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Tone Co., Ltd. (5967.T) Income Statement Analysis – Financial Results
- Harbor Bankshares Corporation (HRBK) Income Statement Analysis – Financial Results
- Enbridge Inc (ENB-PT.TO) Income Statement Analysis – Financial Results
- EFC (I) LIMITED (EFCIL.BO) Income Statement Analysis – Financial Results
- public-stock company Tomsk distribution company (TORS.ME) Income Statement Analysis – Financial Results
Zhejiang Cheng Yi Pharmaceutical Co., Ltd. (603811.SS)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.chengyipharma.com
About Zhejiang Cheng Yi Pharmaceutical Co., Ltd.
Zhejiang Cheng Yi Pharmaceutical Co., Ltd. produces and sells APIs and capsules/tablets in China. The company was formerly known as Wenzhou No. 3 Pharmaceutical Factory and changed its name to Zhejiang Cheng Yi Pharmaceutical Co., Ltd. in April 2001. Zhejiang Cheng Yi Pharmaceutical Co., Ltd. was founded in 1966 and is headquartered in Wenzhou, China.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 671.63M | 654.97M | 693.96M | 758.13M | 681.23M | 545.77M | 340.89M | 321.22M | 316.95M | 320.23M | 266.06M | 255.43M | 215.28M |
| Cost of Revenue | 240.60M | 206.81M | 192.60M | 194.17M | 183.12M | 194.82M | 163.25M | 157.06M | 148.60M | 156.10M | 148.02M | 148.92M | 138.32M |
| Gross Profit | 431.03M | 448.16M | 501.36M | 563.96M | 498.11M | 350.94M | 177.65M | 164.17M | 168.36M | 164.14M | 118.04M | 106.51M | 76.96M |
| Gross Profit Ratio | 64.18% | 68.42% | 72.25% | 74.39% | 73.12% | 64.30% | 52.11% | 51.11% | 53.12% | 51.26% | 44.36% | 41.70% | 35.75% |
| Research & Development | 47.14M | 44.30M | 39.72M | 31.79M | 29.57M | 26.26M | 13.13M | 15.17M | 15.91M | 10.83M | 11.13M | 9.17M | 0.00 |
| General & Administrative | 15.52M | 23.42M | 28.77M | 20.65M | 15.87M | 12.64M | 15.45M | 12.63M | 12.85M | 16.20M | 36.86M | 31.94M | 29.59M |
| Selling & Marketing | 121.54M | 180.69M | 200.56M | 272.12M | 267.35M | 167.22M | 45.80M | 35.12M | 45.14M | 45.14M | 32.20M | 33.01M | 26.98M |
| SG&A | 137.06M | 204.11M | 229.33M | 292.77M | 283.22M | 179.86M | 61.25M | 47.74M | 57.99M | 61.34M | 69.06M | 64.95M | 56.57M |
| Other Expenses | 72.91M | 63.75M | 67.60M | 54.26M | 28.40M | 188.38K | 3.49M | 3.80M | 4.32M | 2.15M | 2.23M | 2.15M | 834.56K |
| Operating Expenses | 257.12M | 312.17M | 336.65M | 378.83M | 341.19M | 241.72M | 100.29M | 88.21M | 97.88M | 94.64M | 71.32M | 66.88M | 57.98M |
| Cost & Expenses | 497.72M | 518.98M | 529.25M | 573.00M | 524.31M | 436.54M | 263.53M | 245.27M | 246.48M | 250.74M | 219.34M | 215.80M | 196.31M |
| Interest Income | 8.98M | 2.40M | 1.34M | 2.12M | 3.22M | 1.80M | 390.55K | 145.70K | 100.88K | 228.58K | 0.00 | 5.85M | -0.47 |
| Interest Expense | 15.33M | 9.13M | 4.52M | 4.96M | 494.20K | 731.48K | 109.06K | 800.72K | 1.82M | 3.03M | 2.49M | 0.00 | 8.39M |
| Depreciation & Amortization | 78.79M | 63.22M | 55.83M | 48.79M | 22.80M | 19.63M | 16.24M | 15.50M | 15.79M | 15.66M | 13.36M | 12.57M | 11.87M |
| EBITDA | 267.44M | 235.34M | 257.06M | 241.72M | 175.55M | 131.08M | 96.24M | 93.49M | 84.27M | 80.38M | 58.28M | 52.21M | 30.84M |
| EBITDA Ratio | 39.82% | 37.66% | 38.29% | 33.66% | 26.53% | 24.80% | 29.94% | 30.57% | 29.55% | 28.40% | 23.44% | 21.05% | 15.29% |
| Operating Income | 173.91M | 164.43M | 198.54M | 190.36M | 154.29M | 112.71M | 78.83M | 75.71M | 64.54M | 63.23M | 40.82M | 32.31M | 14.67M |
| Operating Income Ratio | 25.89% | 25.10% | 28.61% | 25.11% | 22.65% | 20.65% | 23.12% | 23.57% | 20.36% | 19.74% | 15.34% | 12.65% | 6.81% |
| Total Other Income/Expenses | 152.94K | -587.93K | -1.03M | -1.47M | -1.34M | -2.05M | 3.49M | 3.22M | 3.62M | 1.83M | 1.74M | -5.12M | 163.82K |
| Income Before Tax | 174.06M | 163.84M | 197.50M | 188.89M | 152.94M | 112.89M | 82.32M | 79.22M | 68.16M | 65.06M | 42.56M | 33.70M | 14.83M |
| Income Before Tax Ratio | 25.92% | 25.01% | 28.46% | 24.92% | 22.45% | 20.69% | 24.15% | 24.66% | 21.51% | 20.32% | 16.00% | 13.19% | 6.89% |
| Income Tax Expense | 12.01M | 2.66M | 26.27M | 23.94M | 21.98M | 15.50M | 13.08M | 11.05M | 10.46M | 11.21M | 6.06M | 4.40M | 1.48M |
| Net Income | 162.90M | 161.58M | 170.80M | 165.14M | 131.39M | 96.91M | 69.24M | 68.17M | 57.71M | 53.85M | 36.50M | 29.30M | 13.35M |
| Net Income Ratio | 24.25% | 24.67% | 24.61% | 21.78% | 19.29% | 17.76% | 20.31% | 21.22% | 18.21% | 16.82% | 13.72% | 11.47% | 6.20% |
| EPS | 0.50 | 0.49 | 0.52 | 0.50 | 0.40 | 0.30 | 0.32 | 0.28 | 0.23 | 0.22 | 0.15 | 0.17 | 0.08 |
| EPS Diluted | 0.50 | 0.49 | 0.52 | 0.50 | 0.40 | 0.30 | 0.32 | 0.28 | 0.23 | 0.22 | 0.15 | 0.17 | 0.08 |
| Weighted Avg Shares Out | 325.79M | 327.30M | 327.30M | 327.30M | 327.30M | 327.30M | 218.38M | 244.75M | 246.29M | 246.25M | 245.94M | 175.70M | 175.70M |
| Weighted Avg Shares Out (Dil) | 325.79M | 327.30M | 327.30M | 327.30M | 327.30M | 328.30M | 218.38M | 244.75M | 246.31M | 246.29M | 245.98M | 175.70M | 175.70M |
Source: https://incomestatements.info
Category: Stock Reports